Balance Sheet
Cash Flow Statement
Asset Writedowns and ImpairmentCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsCash from RestructuringChange in Account PayablesChange in Accured ExpensesChange in CashDepreciation & Amortization (CF)Depreciation and DepletionFree Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeOther financing activitiesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Lyra Therapeutics (LYRA) Cash from Financing Activities (2021 - 2025)

Lyra Therapeutics (LYRA) has disclosed Cash from Financing Activities for 5 consecutive years, with -$368000.0 as the latest value for Q3 2025.

  • On a quarterly basis, Cash from Financing Activities fell 1500.0% to -$368000.0 in Q3 2025 year-over-year; TTM through Sep 2025 was -$481000.0, a 101.75% decrease, with the full-year FY2024 number at $8.5 million, down 87.01% from a year prior.
  • Cash from Financing Activities was -$368000.0 for Q3 2025 at Lyra Therapeutics, down from -$1000.0 in the prior quarter.
  • In the past five years, Cash from Financing Activities ranged from a high of $96.5 million in Q2 2022 to a low of -$418000.0 in Q3 2023.
  • A 5-year average of $10.7 million and a median of $1500.0 in 2023 define the central range for Cash from Financing Activities.
  • Peak YoY movement for Cash from Financing Activities: skyrocketed 216000.0% in 2024, then crashed 1500.0% in 2025.
  • Lyra Therapeutics' Cash from Financing Activities stood at -$4000.0 in 2021, then plummeted by 5800.0% to -$236000.0 in 2022, then skyrocketed by 8116.95% to $18.9 million in 2023, then tumbled by 100.01% to -$1000.0 in 2024, then plummeted by 36700.0% to -$368000.0 in 2025.
  • Per Business Quant, the three most recent readings for LYRA's Cash from Financing Activities are -$368000.0 (Q3 2025), -$1000.0 (Q4 2024), and -$23000.0 (Q3 2024).